Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma

被引：0
|
作者：
Arribas, A. [1 ]
Napoli, S. [1 ]
Cascione, L. [1 ]
Gaudio, E. [1 ]
Bordone-Pittau, R. [2 ]
Barreca, M. [3 ]
Sartori, G. [1 ]
Chiara, T. [1 ]
Spriano, F. [1 ]
Rinaldi, A. [1 ]
Stathis, A. [4 ]
Stussi, G. [5 ]
Rossi, D. [4 ]
Emanuele, Z. [4 ]
Bertoni, F. [1 ]
机构：
[1] Fac Biomed Sci USI, Oncol Res Inst, Bellinzona, Switzerland
[2] Oncol Inst Southern Switzerland, Ematol Lab Ematol EOLAB, Bellinzona, Switzerland
[3] Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol, Palermo, Italy
[4] Oncol Inst Southern Switzerland, Fac Biomed Sci USI, Bellinzona, Switzerland
[5] Oncol Inst Southern Switzerland, Ematol Unita Leucemie IOSI, Bellinzona, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
149
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [31] Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Ferry Eskens
    George Blumenschein
    Donald Richards
    Isabelle Genvresse
    Susanne Reschke
    Camille Granvil
    Adam Skubala
    Carol Peña
    Klaus Mross
    Targeted Oncology, 2020, 15 : 163 - 174
  • [32] Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, idolent or aggressive lymphoma
    Follows, G.
    Dreyling, M.
    Linton, K.
    Grunert, J.
    Hiemeyer, F.
    Giurescu, M.
    Childs, B. H.
    Cunningham, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 21 - 21
  • [33] Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Eskens, Ferry
    Blumenschein, George, Jr.
    Richards, Donald
    Genvresse, Isabelle
    Reschke, Susanne
    Granvil, Camille
    Skubala, Adam
    Pena, Carol
    Mross, Klaus
    TARGETED ONCOLOGY, 2020, 15 (02) : 163 - 174
  • [34] Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
    Krause, Guenter
    Hassenrueck, Floyd
    Hallek, Michael
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 2577 - 2590
  • [35] Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma
    Dreyling, M.
    Zinzani, P. L.
    Bouabdallah, K.
    Bron, D.
    Cunningham, D.
    Linton, K.
    Thieblemont, C.
    Van den Neste, E.
    Vitolo, U.
    Grunert, J.
    Giurescu, M.
    Mappa, S.
    Childs, B. H.
    Morschhauser, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 162 - 163
  • [36] The PI3Kδ inhibitor, idelalisib, inhibits transcription and translation through PI3K/Akt pathway in mantle cell lymphoma
    Yang, Qingshan
    Chen, Lisa S.
    Neelapu, Sattva S.
    Gandhi, Varsha
    CANCER RESEARCH, 2014, 74 (19)
  • [37] EFFICACY OF THE PAN PI3K-INHIBITOR COPANLISIB COMPARED TO SELECTIVE PI3K-A, -B, -Δ INHIBITORS IN MANTLE CELL LYMPHOMA (MCL)
    Zoellner, A.
    Arnd, J.
    Hutter, G.
    Zimmermann, Y.
    Hiddemann, W.
    Dreyling, M.
    HAEMATOLOGICA, 2015, 100 : 551 - 551
  • [38] Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma
    Panayiotidis, Panayiotis
    Follows, George A.
    Mollica, Luigina
    Nagler, Arnon
    Ozcan, Muhit
    Santoro, Armando
    Stevens, Don
    Trevarthen, David
    Hiemeyer, Florian
    Garcia-Vargas, Jose
    Childs, Barrett H.
    Zinzani, Pier Luigi
    Dreyling, Martin
    BLOOD ADVANCES, 2021, 5 (03) : 823 - 828
  • [39] Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
    Guidetti, Francesca
    Arribas, Alberto J.
    Sartori, Giulio
    Spriano, Filippo
    Barnabei, Laura
    Tarantelli, Chiara
    Von Roemeling, Reinhard
    Martinez, Elizabeth
    Zucca, Emanuele
    Bertoni, Francesco
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
  • [40] Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma
    Larson, Sarah M.
    Peng, Mao Yu
    Mead, Monica
    Vandross, Andrae
    Conklin, Dylan
    Von Euw, Erika
    Slamon, Dennis J.
    BLOOD, 2017, 130
12345